Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Clues to prostate cancer risk in blood samples taken 15 years earlier (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of nine claims match the study. This overall rating is based only on the claims we could check. Six claims the study doesn't address.

  • 3 supported
  • 6 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

9 claims in this story

Showing all 9 claimsChoose a verdict to focus the list.

Claim 1 of 9Not coveredThe study used men from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 982 prostate cancer cases and a subcohort of 1,573 men, with a median potential follow-up of 16.5 years, and measured 6,412 plasma proteins.View evidenceHide evidence

As stated982 cases; 1,573 subcohort members; 6,412 plasma proteins; 16.5 years

Why this verdict

The abstract-level profile supports the EPIC case-cohort design, 982 incident cases, 1573 subcohort participants, and SomaScan measurement of over 6000 proteins. However, it does not verify the exact 6412-protein count or the stated median potential follow-up of 16.5 years at this evidence depth.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 2 of 9Not coveredSeven proteins were associated with aggressive prostate cancer risk, including ANKRD1 and TPM3, and ANKRD1 was reported across high-grade, advanced-stage, and lethal disease categories.View evidenceHide evidence

As statedHR 1.25 for ANKRD1 and TPM3; 23% to 29% increase in hazard for ANKRD1 across aggressive categories

Why this verdict

The profile supports that seven proteins were associated with aggressive prostate cancer and that ANKRD1 was consistently associated across multiple clinically relevant subtypes. But the abstract-level profile does not verify TPM3, the specific high-grade/advanced-stage/lethal categories, or the stated HR values.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 3 of 9Not coveredNine proteins were associated with cancers diagnosed within five years of blood collection, while another 12 were linked to cancers diagnosed more than 15 years later, suggesting that some associations may emerge long before diagnosis.View evidenceHide evidence

As statedwithin five years; more than 15 years later

Why this verdict

The profile supports the claim that twelve proteins were associated with prostate cancers diagnosed more than 15 years after blood draw. It does not verify at abstract depth the additional assertion that nine proteins were associated with cancers diagnosed within five years.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 4 of 9Not coveredHigher levels of GZMK and ANXA2 were associated with lower prostate cancer risk over the longer term, while IL-17B and OSCAR were associated with higher long-term risk.View evidenceHide evidence

As stated43% and 38% lower hazard for GZMK and ANXA2

Why this verdict

The abstract-level profile identifies ANXA2, GZMK, and OSCAR among proteins associated with prostate cancer diagnosed more than 15 years after blood draw, and notes ANXA2 consistency in ARIC. It does not provide the direction or effect sizes for GZMK or ANXA2, does not verify IL-17B, and does not state the claimed higher-versus-lower long-term risk pattern.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
2

Study evidence

ACP3 showed a consistent association with future/incident prostate cancer in both EPIC and ARIC.

“Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study”
Claim 5 of 9Not coveredThe researchers also found proteins encoded by ERBB3, KRAS, and NRAS were associated with aggressive disease, and RBFOX1 and CTNNB1 were associated with prostate cancer diagnosed more than 15 years and 5-10 years after blood draw, respectively.View evidenceHide evidence

Why this verdict

The profile supports that circulating products of established prostate cancer driver genes including ERBB3, KRAS, and NRAS were associated with future aggressive disease. It does not verify, at abstract depth, the additional RBFOX1 and CTNNB1 latency-specific associations.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 6 of 9Not coveredThe article says the observational design cannot establish causality, genetic analyses offered only limited support for causal conclusions, and the proteins need further validation before clinical use or prediction beyond PSA.View evidenceHide evidence

Why this verdict

The profile supports the observational nature of the main EPIC and ARIC analyses, incomplete external replication, high-level MR support for only four proteins, rare-variant support for eight proteins/genes, and the authors' call for further validation and mechanistic work. However, the abstract-level profile does not verify the specific phrasing about prediction beyond PSA or fully substantiate the story's detailed characterization of the genetic evidence as only limited for causal conclusions.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
2

Study evidence

ACP3 showed a consistent association with future/incident prostate cancer in both EPIC and ARIC.

“Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study”
Claim 7 of 9SupportedScientists identified blood proteins linked to aggressive prostate cancer years before diagnosis, raising hopes for better risk prediction while uncovering potential roles for immune activity and cancer-related pathways.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that baseline circulating proteins were associated with future aggressive prostate cancer, that some findings implicated immune/angiogenesis/driver-gene pathways, and that the findings may nominate candidate risk factors. The headline is hedged as 'linked' and 'raising hopes,' so it does not assert causality or established clinical utility, though the risk-prediction framing remains aspirational.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 8 of 9SupportedA recent study published in European Urology reports associations between some circulating plasma proteins and prostate cancer, with some predating diagnosis by over a decade.View evidenceHide evidence

As statedover a decade

Why this verdict

The profile supports an EPIC prospective case-cohort study reporting associations between circulating plasma proteins and incident prostate cancer, including twelve proteins associated with cancers diagnosed more than 15 years after blood draw. 'Over a decade' is consistent with the >15-year latency finding.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Claim 9 of 9SupportedThree proteins were associated with overall prostate cancer risk after adjustment and multiple-testing correction: KLK3, ACP3, and FLT4, with KLK3 described as by far the strongest association.View evidenceHide evidence

As statedabout 76% to 128% higher hazard for KLK3; 20% elevated hazard for ACP3; 26% higher hazard for FLT4

Why this verdict

The profile reports ACP3, FLT4, and KLK3 as associated with higher overall prostate cancer risk, with effect sizes matching the stated approximate hazards: ACP3 HR 1.20, FLT4 HR 1.26, and KLK3 HR 2.28 per 1 SD. KLK3 is clearly the strongest of these three associations in the abstract-level results.

1

Study evidence

ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).

“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Rare-variant exome gene-burden analyses supported eight proteins/genes

    The story discusses genetic analyses generally but does not specifically reflect the rare-variant exome gene-burden component or the reported support for eight proteins/genes.

    From Rare-variant exome gene-burden tests (gene-based aggregation)

10 things the story did carry across
  • Primary EPIC prospective case-cohort proteomics analysis of baseline plasma and future prostate cancer risk
  • Use of SomaScan 7k/high-dimensional profiling of over 6000 circulating proteins
  • Overall prostate cancer associations for ACP3, FLT4, and KLK3, with KLK3 the strongest reported overall association
  • Aggressive prostate cancer associations, including seven proteins and consistent ANKRD1 association across clinically relevant subtypes
  • Long-latency findings: twelve proteins associated with prostate cancer diagnosed more than 15 years after blood draw
  • Biological/pathway interpretation involving immune activity, adhesion, angiogenesis, and established prostate cancer driver-gene products
  • External evaluation/replication in ARIC, with consistency for only a subset of proteins and incomplete external replication overall
  • Mendelian randomization used as supportive genetic evidence for four proteins, with limited abstract-level detail
  • Important limitation: differences in endpoint availability across cohorts may affect comparability of validation analyses
  • Need for further external validation and mechanistic evaluation before clinical interpretation
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify baseline circulating plasma proteins associated with future incident overall and aggressive prostate cancer risk in EPIC using high-dimensional SomaScan proteomics (case-cohort prospective analysis).EPIC case-cohort proteomic discoveryExpand

In plain English

Prospective case-cohort analysis within EPIC measured >6000 plasma proteins (SomaScan 7k) at baseline in 982 incident prostate cancer cases and 1573 subcohort participants and used Prentice-weighted Cox models to identify proteins associated with future overall and aggressive prostate cancer. Several proteins (including ACP3, FLT4, KLK3) were associated with overall PCa risk, seven proteins (including ANKRD1) with aggressive PCa, and twelve proteins with diagnoses >15 years after blood draw; some findings were supported in ARIC, by Mendelian randomization, and by rare-variant burden tests. The authors highlight pathway groups (immune, adhesion, angiogenesis, driver-gene products) and call for further validation and mechanistic work.

Key findings

  • ACP3, FLT4, and KLK3 were positively associated with incident overall prostate cancer in EPIC.ACP3 HR per 1 SD 1.20 (95% CI 1.10-1.31); FLT4 HR per 1 SD 1.26 (95% CI 1.13-1.40); KLK3 HR per 1 SD 2.28 (95% CI 1.96-2.65).
  • Seven proteins were associated with risk of aggressive prostate cancer, with ANKRD1 consistently associated across multiple clinically relevant disease subtypes.
“In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins).”
What this piece can’t prove
  • Incomplete external replication across evaluated cohorts as reported by the authors.
  • Differences in end point availability across cohorts which may affect comparability of replication/validation analyses.
  • Abstract does not provide complete effect-size estimates or statistical details for all reported proteins/subgroup analyses.
2secondary dataExternally evaluate/replicate key protein–prostate cancer associations in an independent prospective cohort (ARIC).External validation in ARIC (prospective cohort replication)Expand

In plain English

An independent evaluation of selected EPIC-derived plasma protein–prostate cancer associations was performed in the Atherosclerosis Risk in Communities (ARIC) cohort. ARIC provided consistency evidence for a subset of proteins (ACP3, ANXA2, APOC2, KLK3), but replication was incomplete and endpoint availability differed between cohorts; ARIC-specific effect estimates and analytic details are not reported in the abstract.

Key findings

  • ACP3 showed a consistent association with future/incident prostate cancer in both EPIC and ARIC.
  • ANXA2 showed a consistent association with future/incident prostate cancer in both EPIC and ARIC.
“Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study”
What this piece can’t prove
  • External replication was incomplete; not all EPIC-identified proteins were validated in ARIC.
  • Differences in endpoint availability across cohorts may limit comparability of ARIC and EPIC results.

1 further detail could not be confirmed from the summary.

3secondary dataAssess potential causal support for selected protein associations using Mendelian randomization (MR).Mendelian randomization (genetic-instrument causal inference)Expand

In plain English

The study applied Mendelian randomization (MR) as a genetic-instrument sensitivity/causal analysis to evaluate whether selected circulating proteins associated with future prostate cancer risk in prospective proteomic analyses have supportive genetic evidence. In the abstract the authors report that four proteins showed support from MR analyses, but no MR-specific details (instrument selection, strength, analytic method, or effect estimates) are provided in the abstract.

Key findings

  • Mendelian randomization analyses provided support for associations between four circulating proteins and future prostate cancer risk.
“Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study and supported by Mendelian randomization (MR) and exome gene-burden analyses.”
What this piece can’t prove
  • Incomplete external replication of findings noted by the authors.
  • Differences in endpoint availability across cohorts may limit comparability and generalizability of MR support.

1 further detail could not be confirmed from the summary.

4secondary dataSupport implicated proteins/genes via rare-variant exome gene-burden analyses.Rare-variant exome gene-burden tests (gene-based aggregation)Expand

In plain English

The study reports that exome rare-variant gene-burden (gene-based aggregation) analyses were used as supportive genetic evidence for proteins/genes implicated by the prospective plasma proteomic analyses; the abstract states that eight proteins/genes had support from rare-variant burden tests.

Key findings

  • Exome rare-variant gene-burden analyses provided support for eight proteins/genes implicated in the study.
“Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study and supported by Mendelian randomization (MR) and exome gene-burden analyses.”
What this piece can’t prove
  • Abstract provides no methodological or statistical detail for the exome rare-variant burden analyses (e.g., cohort/sample size, variant selection, gene-based test, significance thresholds).
  • The abstract does not specify which genes/proteins were supported by the burden tests.
  • Authors note incomplete external replication and differences in end-point availability across cohorts, which may limit interpretation of the burden-test support.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer

2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.